Private Equity Archives - Gilde Healthcare

Menu
Menu
Home

latest news
Private Equity

Gilde Healthcare’s Private Equity fund sells majority stake in European CRO/CDMO Symeres to Keensight Capital

Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout1 investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). According to the terms of the agreement, Keensight Capital will acquire a majority stake in Symeres from the Gilde...
May 25, 2021

Gilde Healthcare acquires majority stake in Danish drug development consultancy KLIFO to support international growth ambitions

Northern European integrated drug development consultancy aims to further expand service offering and geographical footprint Utrecht (the Netherlands) and Copenhagen (Denmark) – Gilde Healthcare, a specialized healthcare investor, and KLIFO A/S, a leading Northern European drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects, today […]

The Private Equity fund of Gilde Healthcare acquires German medtech company Acti-Med

Investment to support the global expansion of leading manufacturer of precision medical components and devices Utrecht (the Netherlands) and Freienstau – The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired Acti-Med, a leading international developer and contract manufacturer of high-quality medical components and devices for the medical and pharmaceutical industries. Founded […]

Gilde Healthcare supports national roll out of dental chain Tandarts Today

Utrecht and Eindhoven (the Netherlands) – Gilde Healthcare, a specialized healthcare investor with €1.4 billion under management, announces its investment in dental chain Tandarts Today. With this acquisition, Gilde Healthcare enters the Dutch Dental Care Market with its attractive market dynamics and prevailing growth opportunities. Eindhoven-based Tandarts...

RAD-x adds Medizin Center Bonn to its fast growing diagnostic imaging platform

Utrecht (the Netherlands) and Mannheim (Germany) – RAD-x, the leading European diagnostic imaging practice operator and portfolio company of Gilde Healthcare Private Equity, is adding Medizin Center Bonn (MCB) to its group. MCB provides cutting-edge premier nuclear medicine- and radiology services in the region of Bonn, NRW,...

Ace Pharmaceuticals strengthens shareholders base

Zeewolde, the Netherlands – Ace Pharmaceuticals (Ace), a specialized pharmaceutical company in medical need medicines, strengthens its shareholders base with the addition of Gilde Buy Out Partners and Gilde Healthcare. Founded in 1990 and based in Zeewolde, Ace focuses on the development, production and distribution of licensed...

RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group

Utrecht (the Netherlands) – RAD-x is welcoming Radiologisches Zentrum Lahnstein (“RZL”) in its group. Radiologisches Zentrum Lahnstein is a provider of diagnostic imaging services in the region Koblenz, Germany. Its three radiologists and almost 30 staff serve the community in and around Lahnstein and provide imaging services...

MercachemSyncom changes name to Symeres

Nijmegen (The Netherlands) – MercachemSyncom today announced that it will change its name and operate under the registered trade name of Symeres.   The new name reflects the strategic evolution of the company, with the growth of integrated drug discovery and development services, which complement the company’s...

Drug discovery CRO MercachemSyncom adds biology services through acquisition

Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, today announced that it has acquired Admescope Ltd., a provider of ADME-Tox services, based in Oulu (Finland) and Södertälje (Sweden). The acquisition of Admescope allows MercachemSyncom to significantly expand its...
Loading...
These were all messages
0581a22153